Quickly compare the immunogenic potential of small to large sets of biologic sequences.
Easily identify low-risk candidates to bring forward in development by leveraging top-tier in silico tools.
Save time and money by reducing laboratory work (on average, more than 20-fold).
Rapidly identify your low-risk candidates.
The ISPRI Downselect™ analysis is a high-level evaluation of the immunogenic potential of a set of biologic therapy candidates. The analysis is typically utilized to rank and inform the selection of high-quality candidates to advance to further development. The analysis, which can be performed on a few to many candidates, is executed by immunoinformatics experts leveraging EpiVax’s proprietary ISPRI™ in silico toolkit. Results summarizing the T cell epitope content and “humanness” of the whole biologic sequence are provided in a tabulated report, including visual aids that enable the comparison of the immunogenic risk of the sequences of interest. The analysis is accompanied by a discussion with EpiVax experts.
Modalities
Sample ISPRI Downselect™ Quadrant Plot
ISPRI Downselect™ data outputs include a quadrant plot like the one to the right, allowing for comparative categorization and visualization of the immunogenic potential of your candidates. T cell epitope content (EpiMatrix) is plotted along the y-axis. A high EpiMatrix score represents an abundance of epitopes and consequently, an elevated immunogenic risk. Human homology (JanusMatrix) is plotted along the x-axis. A high JanusMatrix score represents significant cross-conservation with epitopes derived from the human proteome and higher likelihood that the therapeutic will be tolerated by the immune system.
Need actionable immunogenicity data?
Learn more about ISPRI Downselect™!
The EpiVax Roadmap
